Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
23:23
Apple requests the US Supreme Court to review the contempt order in the Epic Games lawsuit
The ruling determined that the iPhone manufacturer was found in civil contempt of court for charging fees to its App Store users for certain third-party purchases made within apps. A petition filed with the Supreme Court further escalates the years-long legal dispute between Apple and the Fortnite developer, Epic Games. Epic Games sued Apple in 2020 aiming to loosen Apple’s control over in-app transactions on its iOS operating system, as well as restrictions on how apps can be distributed to consumers. Although a judge largely dismissed Epic's lawsuit, an injunction was issued in 2021 requiring Apple to allow developers to include links within apps directing users to non-Apple payment options. Apple permitted such links but implemented new restrictions, including charging developers a 27% commission—this fee applies to purchases completed through payment systems outside the App Store within seven days after a user clicks the link. Epic argues that this new 27% commission violates the prior injunction. In 2025, the judge ruled that Apple was in civil contempt of court for violating the injunction. On Thursday, Apple urged the Justices to review two legal issues. The company stated the injunction should not apply to millions of developers because Epic is the sole plaintiff and the case is not a class action. Apple further argued that it cannot be found in contempt for allegedly violating the "spirit" of the injunction, as the order did not explicitly prohibit the conduct in question. Apple denies any wrongdoing and states that it is complying with the court’s orders.
23:23
Biogen and Denali report that their Parkinson's disease drug did not meet the trial endpoint
The two pharmaceutical companies said on Thursday that, in light of the trial results, they will halt further development of BIIB122 for the treatment of idiopathic Parkinson's disease. Denali's share price fell 7% to $18, while Biogen's share price dipped 1% to $187.49. BIIB122 is currently in a phase 2b trial aimed at treating early-stage Parkinson's disease, but the study failed to meet its primary or secondary endpoints.
22:57
Strengthening environmental review! The U.S. government allows the Dakota Access Pipeline to continue operations
The prerequisites for maintaining operations include upgrading the leak detection system, enhancing real-time monitoring of surface and groundwater bodies, and introducing third-party independent agencies to conduct safety assessments of the pipeline leak prevention system. The federal government has explicitly stated that this approval does not include authorization to construct any new pipeline extensions.
News